Formulation, optimization, characterization and in-vitro drug release kinetics of atenolol loaded PLGA nanoparticles using 3 3 factorial design for oral delivery

Chourasiya, Vibha; Bohrey, Sarvesh; Pandey, Archna

doi:10.1016/j.md.2016.12.002

Cited by 41 publications

(22 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increase in cell uptake however does not reflect an increase in cell killing efficiency of the MTO TMV formulation compared to free MTO – this may be explained by slower metabolism of the drug by the tumor cells, due to the added barrier of MTO encapsulation. 26…”

Section: Resultsmentioning

confidence: 99%

Tobacco mosaic virus delivery of mitoxantrone for cancer therapy

Lin

Steinmetz

2018

Nanoscale

View full text Add to dashboard Cite

Mitoxantrone (MTO) is a topoisomerase II inhibitor which has been used to treat various forms of cancer either as a solo chemotherapy regimen or as a component in cocktail treatments. However, as with other anti-neoplastic agents, MTO has severe cardiac side effects. Therefore, a drug delivery approach holds promise to improve the safety and applicability of this chemotherapy. Here, we report the application of a plant virus-based nanotechnology derived from tobacco mosaic virus (TMV) as a delivery vehicle for MTO towards cancer therapy. TMV is a high aspect-ratio, soft-matter nanotube with dimensions of 300 × 18 nm and a 4 nm wide channel. The surface chemistry of the interior and exterior TMV surfaces is distinct and we established charge-driven drug loading strategies to encapsulate therapeutics for drug delivery. We demonstrate effective MTO loading into TMV yielding ∼1000 MTO per TMV carrier. The treatment efficacy of MTO-loaded TMV (MTOTMV) was assessed in in vitro and in vivo models. In vitro testing confirmed that MTO maintained its efficacy when delivered by TMV in a panel of cancer cell lines. Drug delivery in vivo using a mouse model of triple negative breast cancer demonstrated the superior efficacy of TMV-delivered MTO vs. free MTO. This study demonstrates the potential of plant virus-based nanotechnology for cancer therapy and drug delivery.

show abstract

Section: Resultsmentioning

confidence: 99%

Tobacco mosaic virus delivery of mitoxantrone for cancer therapy

Lin

Steinmetz

2018

Nanoscale

View full text Add to dashboard Cite

show abstract

“…Assessment of in vitro drug release kinetics was performed using a dialysis diffusion technique (Chourasiya et al., 2016 ; Stein et al., 2018 ; Hsu et al., 2020 ). GEM-CPT-11 NPs (3 mL), and CPT-11 and GEM (0.1 mg/mL equivalent concentration) solutions were placed into the end-wrapped dialysis covers.…”

Section: Methodsmentioning

confidence: 99%

Combinational dual drug delivery system to enhance the care and treatment of gastric cancer patients

Xiao

Gao

et al. 2020

Drug Delivery

View full text Add to dashboard Cite

Gastric cancer is a frequently occurring cancer with high mortality each year worldwide. Finding new and effective therapeutic strategy against human gastric cancer is still urgently required. Hence, we have established a new method to achieve treatment-actuated modifications in a tumor microenvironment by utilizing synergistic activity between two potential anticancer drugs. Dual drug delivery of gemcitabine (GEM) and Camptothecin-11 (CPT-11) exhibits a great anti-cancer potential, as GEM enhances the effect of CPT-11 treatment of human gastric cells by providing microenvironment stability. However, encapsulation of GEM and CPT-11 obsessed by poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles (NPs) is incompetent owing to unsuitability between the binary free GEM and CPT-11 moieties and the polymeric system. Now, we display that CPT-11 can be prepared by hydrophobic covering of the drug centers with dioleoylphosphatidic acid (DOPA). The DOPA-covered CPT-11 can be co-encapsulated in PLGA NPs alongside GEM to stimulate excellent anticancer property. The occurrence of the CPT-11 suggestively enhanced the encapsulations of GEM into PLGA NPs (GEM-CPT-11 NPs). Formation of the nanocomposite (GEM-CPT-11 NPs) was confirmed by FTIR and X-ray spectroscopic techniques. Further, the morphology of GEM NPs, CPT-11 NPs, and GEM-CPT-11 NPs and NP size was examined by transmission electron microscopy (TEM), respectively. Furthermore, GEM-CPT-11 NPs induced significant apoptosis in human gastric NCI-N87 and SGC-791 cancer cells in vitro. The morphological observation and apoptosis were confirmed by the various biochemical assays (AO-EB, nuclear staining, and annexin V-FITC). In addition, evaluation of the hemolysis assay with erythrocytes of human shows excellent biocompatibility of free GEM, free CPT-11, GEM NPs, CPT-11 NPs, and GEM-CPT-11 NPs. The results suggest that GEM-CPT-11 NPs are one of the promising nursing cares for human gastric cancer therapeutic candidates worthy of further investigations.

show abstract

“…The validation of the present statistical experimental design was associated with the performance of these random checkpoint formulations. 3,30,31 Moreover, the optimized formulation was selected from the checkpoint list in view of the maximum value of desirability and the minimum percentage of errors and was further utilized for nanoformulation batch preparation and characterization. 2.2.4.3.…”

Section: Preparation Of Paclitaxel and Lansoprazole Dual Drugloaded Nmentioning

confidence: 99%

“…The kinetics of PTX and LAN release from the optimized nanoformulation were determined by tting the obtained data to various kinetic models, [35][36][37][38][39][40] including the zero order release model (eqn (4)), rst order release model (eqn (5)), Higuchi model (eqn (6)) and Korsmeyer-Peppas model (eqn (7)): 21,31…”

Section: Preparation Of Paclitaxel and Lansoprazole Dual Drugloaded Nmentioning

confidence: 99%

A chemotherapeutic approach targeting the acidic tumor microenvironment: combination of a proton pump inhibitor and paclitaxel for statistically optimized nanotherapeutics

et al. 2019

View full text Add to dashboard Cite

show abstract

Formulation, optimization, characterization and in-vitro drug release kinetics of atenolol loaded PLGA nanoparticles using 3 3 factorial design for oral delivery

Cited by 41 publications

References 32 publications

Tobacco mosaic virus delivery of mitoxantrone for cancer therapy

Tobacco mosaic virus delivery of mitoxantrone for cancer therapy

Combinational dual drug delivery system to enhance the care and treatment of gastric cancer patients

A chemotherapeutic approach targeting the acidic tumor microenvironment: combination of a proton pump inhibitor and paclitaxel for statistically optimized nanotherapeutics

Contact Info

Product

Resources

About